Windlas Biotech Limited (NSE:WINDLAS)

Market Cap	16.87B -11.2%
Revenue (ttm)	8.68B +19.2%
Net Income	667.47M +8.2%
EPS	31.44 +7.4%
Shares Out	20.96M
PE Ratio	25.60
Forward PE	n/a
Dividend	5.80 (0.72%)
Ex-Dividend Date	Jul 21, 2025

Volume	11,744
Average Volume	46,251
Open	798.00
Previous Close	804.90
Day's Range	787.20 - 818.00
52-Week Range	665.10 - 1,140.00
Beta	0.26
RSI	47.55
Earnings Date	Feb 5, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,346
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WINDLAS

Financial Performance

In fiscal year 2025, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.